Latest Packaging News

QEM has completed its move into Idaho, acquiring the Big It and Garden Valley projects and outlining staged exploration of historical tungsten, antimony, gold and rare-metal targets. The company ended September with $3.98 million in cash while keeping major Julia Creek expenditure on hold.

Orora says strong Cans growth is no longer enough to offset weaker Saverglass earnings, with Group EBIT expected to decline in FY27. The company is targeting more than €30 million in Glass EBIT improvement by FY30 after a €449.7 million non-cash impairment.

Biotron has appointed Glenn Gilbert as chief executive and executive director, bringing more than two decades of pharmaceutical, medical device and diagnostics experience to the company’s SedRx and antiviral programs. His package combines a $250,000 salary with up to 100 million performance-based options and $230,000 in milestone-linked cash bonuses.

Latrobe Magnesium has given eligible shareholders an additional 10 days to participate in its fully underwritten entitlement offer, citing market volatility and delays in receiving offer documents. The revised deadline is 26 October, with new shares expected to begin trading on 3 November.

ReNerve has received supportive FDA feedback on the preclinical and testing pathway for its NervAlign Nerve Guide Matrix. The guidance sharpens the route towards a US submission, but does not amount to clearance and leaves the submission timetable open.

LGI Limited (ASX:LGI) will elevate current CEO Jarryd Doran to Managing Director and CEO while reshaping its board and executive team from 1 December. The restructure includes 5.861 million proposed options for Doran and other executives, with shareholder approval required for the grants.

Core Lithium has moved Finniss into the next phase of its restart, producing first spodumene concentrate and targeting an initial shipment in the December quarter. The company ended September with A$199.7 million in cash, while BP33 development and high-grade exploration continued in parallel.

IAG has offered a package of competition remedies to support approval of its proposed 20-year insurance alliance with RAC of Western Australia, including the transfer of NRMA policy renewal rights and a $20 million community investment. The insurer says the transaction still carries $1.2 billion in additional annual gross written premium and approximately $100 million in annual pre-tax synergies once integration is complete.

Talga has moved Talnode-C from qualification into commercial shipments, completed key engineering work for its staged Vittangi project and secured major Swedish permits. But the battery materials developer remains loss-making, cash-burning and reliant on further funding to continue development.

Tusker Minerals has completed the sale of its Malawi exploration subsidiary to AuKing Mining, receiving $800,000 in cash and 40 million escrowed AuKing shares. The deal gives Tusker further deferred and performance-linked consideration while redirecting its immediate funding capacity towards Cameroon and the retained Mzimba project.

Delorean Corporation has secured a non-binding $20 million financing mandate from Westpac for its NSW1 Horsley Park bioenergy project, taking identified funding to about 81% of the estimated build cost. The project still needs binding finance documents and a further $11.6 million before financial close can be reached.

Prescient Therapeutics has reached the first planned review threshold in its PTX-100 Phase 2a lymphoma study, while a completed A$6.0 million raise extends funding beyond the December milestone. The review will assess safety and efficacy, but is not a study completion or a new clinical result.